first-line setting

Oncology

ESMO 2025 in review: A new era in oncology, from AI to next-...

ESMO 2025 reflected a field in the midst of rapid evolution – one that is increasingly defined by personalisation and data-driven decision-making.

News

Bayer reveals data behind asundexian's stroke win

Bayer's oral Factor XIa inhibitor asundexian can reduce the risk of a secondary ischaemic stroke by 26%, according to the OCEANIC-STROKE trial.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Sales & Marketing

Physicians walking and using tablet devices

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Editor's Picks